

Totalt oversolgt.
2-3 dollars rebound muligt. Target 8.
Så er der lagt i kakkelovnen.
Ingen anbefalinger. Mine handler.
2-3 dollars rebound muligt. Target 8.
Så er der lagt i kakkelovnen.
Ingen anbefalinger. Mine handler.


Immune Design (Nasdaq: IMDZ) 4.5% HIGHER; announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for G100, Immune Designs investigational intratumoral therapy, for the treatment of follicular non-Hodgkins lymphoma.